Lotilibcin

Drug Profile

Lotilibcin

Alternative Names: JA 002; JA 002 - topical; WAP-8294A2

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator aRigen
  • Class Antibacterials; Depsipeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Japan (IV-infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA (Topical, Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top